End Of An Era? AstraZeneca Closes India Research Site Focused On Tropical Diseases
This article was originally published in PharmAsia News
Stakeholders are asking if AstraZeneca remains committed to neglected tropical diseases after the company announces it will close its Indian research unit. The center was the last remaining big pharma basic research center in India.
You may also be interested in...
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
AstraZeneca India R&D Head Balganesh Tanjore On "Drug Hunting" In India To Be At Vanguard Of Innovation
Balganesh Tanjore heads AstraZeneca PLC's innovation efforts in India from the company's Bangalore-based R&D center. The senior scientist is known for his pioneering studies in the field of tuberculosis, having worked on several new compounds. Tanjore keeps a low profile but those in the field of medical research respect his contributions and appreciate his efforts in putting together a very robust innovative infrastructure in India. In a rare media intervew, Tanjore spoke to PharmAsia News' India bureau about "drug hunting" in India, including linking up with academic institutions for better solutions.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.